| Market Cap | 76.91M | P/E | - | EPS this Y | -7.50% | Ern Qtrly Grth | - |
| Income | -40.88M | Forward P/E | -1.24 | EPS next Y | -4.00% | 50D Avg Chg | 10.00% |
| Sales | 665k | PEG | - | EPS past 5Y | - | 200D Avg Chg | 8.00% |
| Dividend | N/A | Price/Book | 0.79 | EPS next 5Y | - | 52W High Chg | -48.00% |
| Recommedations | 1.80 | Quick Ratio | 4.85 | Shares Outstanding | 46.55M | 52W Low Chg | 42.00% |
| Insider Own | 7.25% | ROA | -34.12% | Shares Float | 43.17M | Beta | 1.95 |
| Inst Own | 28.65% | ROE | -58.80% | Shares Shorted/Prior | 6.90M/6.72M | Price | 1.71 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 154,138 | Target Price | 9.67 |
| Oper. Margin | -7,696.32% | Earnings Date | Oct 31 | Volume | 204,678 | Change | -7.57% |
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| PACE GARY W | Director Director | Dec 19 | Buy | 1.37 | 30,000 | 41,100 | 697,761 | 12/19/23 |
| Erlander Mark | Chief Executive Offi.. Chief Executive Officer | Nov 25 | Buy | 1.43 | 10,000 | 14,300 | 24,481 | 11/29/22 |
| White Lale | Director Director | Sep 19 | Buy | 1.635 | 15,000 | 24,525 | 113,788 | 09/20/22 |
| TANNENBAUM RENEE P | Director Director | Sep 15 | Buy | 1.72 | 10,000 | 17,200 | 10,000 | 09/19/22 |
| PACE GARY W | Director Director | Sep 15 | Buy | 1.71 | 150,000 | 256,500 | 644,811 | 09/19/22 |
| Levine James E. | Chief Financial Offi.. Chief Financial Officer | Sep 16 | Buy | 1.557 | 30,000 | 46,710 | 60,000 | 09/19/22 |
| Levine James E. | Chief Financial Offi.. Chief Financial Officer | Sep 13 | Buy | 6.48 | 30,000 | 194,400 | 30,000 | 09/13/21 |
| Kelemen Vicki | Exec. VP and COO Exec. VP and COO | Nov 25 | Option | 2.48 | 35,321 | 87,596 | 40,375 | 11/25/20 |
| Kelemen Vicki | Exec. VP and COO Exec. VP and COO | Nov 25 | Sell | 18.6 | 35,321 | 656,971 | 5,054 | 11/25/20 |